Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

European Diabetes Diagnostics Market

By HospiMedica staff writers
Posted on 26 Sep 2005
Spurred by new techniques that are making diabetes monitoring easier, the European market for diabetes diagnostics is forecast to grow from the current U.S.$265 million to $362 million by 2011, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), a global consulting company.

At least one-third of diabetics are ignorant of their condition. More...
For instance, up to a million of Europe's population with type 2 diabetes remain undiagnosed, creating an urgent need to improve public awareness of diabetes and to encourage regular monitoring. Furthermore, there is a need for improvement in physician and healthcare professional awareness and education in order to understand the complete benefits of laboratory-based testing and frequency.

As part of a public awareness campaign, patients need to be educated about the availability of novel tests and therapies. Innovative techniques are making diabetes monitoring much easier, and cutting-edge glucose meters that are compact and easy to handle are replacing imprecise traditional urine-based tests. These trends toward smaller size and ease of use represent attempts by manufacturers to improve patient accuracy, with components that require less time and blood to measure glucose.

Point-of-care (POC) testing, with its ability to provide rapid and simple results, offers an easy approach to regular monitoring of the disease and is already the largest market in Europe for diabetes diagnostics. While the levels of POC and laboratory testing will remain steady over the next several years, the use of glycated hemoglobin testing is expected to rise slightly as general practitioner surgeries, outpatient clinics, and small hospital-based laboratories adopt the technology more readily.

Nevertheless, the overall progress made in the diabetes diagnostics arena needs to be strengthened through continual efforts to achieve more patient-friendly screening and treatment, with emphasis on better education and training.




Related Links:
Frost & Sullivan

Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.